DJG: Enzyme Immunoassay, Opiates

Product code DJG, “Enzyme Immunoassay, Opiates” in FDA's classification database, is a Class II device type under 21 CFR 862.3650 (opiate test system), reviewed by FDA's Clinical Toxicology panel. FDA's 510(k) database lists 215 clearances under DJG, 82 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
DJG
Regulation
21 CFR 862.3650
Class
II
Panel
Clinical Toxicology
Clearances
215
Most recent
Jan 29, 2026
Median review, last 2 years
83 days
Third-party review
Eligible
Implant
No

What it covers

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

The identification in 21 CFR 862.3650, opiate test system. FDA gives DJG no definition of its own, so the regulation’s describes it.

Recent clearances

510(k)DeviceApplicantDecisionType
K252684Labcorp Fentanyl Urine Visual TestMedtox Diagnostics, Inc.Jan 29, 2026Traditional
K250741Evidence MultiSTAT DOA Urine MultiPlexRandox Laboratories LimitedJan 23, 2026Traditional
K253082LZI Buprenorphine II Enzyme ImmunoassayLin-Zhi International, Inc.Jan 16, 2026Traditional
K252520SEFRIA™ Hydrocodone Oral FluidImmunalysis CorporationSep 11, 2025Traditional
K251972Healgen® AccuFluor Fentanyl Fluorescence Immunoassay (FIA)Test Kit - Qualitative; Healgen® Immunofluorescence Analyzer (OG-H180)Healgen Scientific,, LLCAug 15, 2025Traditional
K251634LZI Fentanyl III Enzyme ImmunoassayLin-Zhi International, Inc.Jun 18, 2025Special
K240124BioSieve™ Fentanyl FIA Test Kit; BioSieve™ ToxiSmart FIA ReaderVivachek Biotech (Hangzhou) Co., Ltd.Jun 14, 2024Traditional
K240698Dochek® Multi-Drug Urine Test Dipcard Rx; Dochek® Multi-Drug Urine Test DipcardGuangzhou Decheng Biotechnology Co., Ltd.May 10, 2024Traditional
K231904Rapid Fentanyl (FYL) Test Strip, Rapid Fentanyl (FYL) Test DipcardCo-Innovation Biotech Co., Ltd.Mar 8, 2024Traditional
K232228Multi-drug Urine Test Cup, Multi-drug Urine Test Dip Card, Accurature Multi-drug Urine Test Cup, Accurature Multi-drug Urine Test Dip CardShanghai Accurature Diagnostics Co., Ltd.Feb 23, 2024Traditional
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 215 with a free account)

Clearances by year

82 DJG 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)3157
2025331
20245150
202310140
20222433
20213422
2020530
20193235
20185134
20174101
20162178
201512141
2014962
2013560
2012595
20116233

Who submits

32 applicants cleared a DJG device since 2011. 77% of the clearances went to applicants in United States, then China (18%) and United Kingdom (5%). By type: Traditional 95% and Special 5%.

ApplicantClearances since 2011
Lin-Zhi International, Inc.11
Immunalysis Corporation8
Guangzhou Wondfo Biotech Co., Ltd.7
Microgenics Corporation6
Ark Diagnostics, Inc.4
Chemtron Biotech, Inc.4
Randox Laboratories Limited4
Siemens Healthcare Diagnostics, Inc.4

How FDA classifies it

Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing.

From 21 CFR 862.3650. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 862.3650 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent DJG clearances declared.

Ask about DJG

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about DJG

What is FDA product code DJG?

Product code DJG, “Enzyme Immunoassay, Opiates” in FDA's classification database, is a Class II device type under 21 CFR 862.3650 (opiate test system), reviewed by FDA's Clinical Toxicology panel. FDA's 510(k) database lists 215 clearances under DJG, 82 of them since 2011.

How many 510(k) clearances are there under DJG?

FDA’s 510(k) database listed 215 clearances under DJG as of Oct 29, 2026, 82 of them decided since 2011; the most recent decision was Jan 29, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a DJG 510(k)?

For the 6 DJG clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 83 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most DJG clearances?

Since 2011: Lin-Zhi International, Inc. (11), Immunalysis Corporation (8), Guangzhou Wondfo Biotech Co., Ltd. (7), Microgenics Corporation (6) and Ark Diagnostics, Inc. (4). 32 applicants have cleared a DJG device in that time.

Sources

  1. FDA product classification: DJG · Product Classification database
  2. 21 CFR 862.3650: Opiate test system · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for DJG · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow DJGGet an email when FDA clears, recalls or publishes guidance for DJG devices.

Know what FDA already cleared.